SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending amid discussions around its partnerships and potential growth in the cybersecurity and IoT sectors, particularly regarding QNX technology. Community members are analyzing technical charts and expressing conviction about the company's long-term prospects, while also pointing to potential manipulation in share price movements. There's optimism related to partnerships with companies like NVIDIA and Microsoft.

What is the project about?  Swisscheese is a groundbreaking blockchain-based platform designed to empower individual investors and promote a completely decentralized financial ecosystem.  What makes your project unique?  Swisscheese's fundamental principle is to democratize investment opportunities by providing a user-driven platform where anybody can buy, sell, swap, pool, stake, and borrow digital assets, particularly traditional stocks represented in the digital world and our native token, SWCH.  History of your project.  It seeks to close the gap between established stock markets and the emerging cryptocurrency industry by building a strong environment where both worlds can communicate without friction.  What’s next for your project?  The Swisscheese platform provides a straightforward, effective, and transparent investing experience, regardless of whether you are an experienced user or a novice exploring the world of digital assets.  What can your token be used for?  Swisscheese is more than just a financial platform, it is the physical act of a desire to bring a new era of financial independence.

SwissCheese

SwissCheese ($SWCH) is trending amid discussions of a potential breakout, with bulls showing strong momentum. Community members are speculating about its potential as a decentralized platform, drawing comparisons to Solana.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

The SLAP crypto community is buzzing with excitement, emphasizing their dedication and constant 'grind.' Discussions revolve around real-world partnerships, including sponsorships with pro athletes like Karolina Arm, generating bullish sentiment. Community members highlight the strong team and the project's potential for significant growth.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors digest Q3 earnings and a record cash pile, with debate focusing on Warren Buffett's cautious stance and the lack of share buybacks. The community is actively discussing the implications of the massive cash reserves amid potential market overvaluation and the company's next strategic moves. Some traders express frustration with the stock's recent performance compared to high-growth tech stocks.

Berkshire Hathaway Inc. - Ordinary Shares - Class A

Berkshire Hathaway is trending as investors digest Q3 earnings, which revealed a record cash pile driven by cautious equity sales and a surge in operating profits fueled by insurance gains. Community discussions revolve around the implications of Warren Buffett's net selling of stocks and paused buybacks, with some speculating about potential acquisitions or a shift in investment strategy.  The surge in cash and lack of buybacks has fueled speculation, with community members joking about Warren Buffet's health and whether or not a market correction is imminent.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential for decentralized applications and AI integration, particularly with the upcoming launch of Caffeine.AI.  Conversations revolve around whether ICP can break through resistance levels and deliver on its promise, contrasting it with other Layer 1 solutions.  Despite some skepticism and past performance concerns, supporters highlight its innovative technology and growing ecosystem.

Roundhill ETF Trust - Roundhill Magnificent Seven Covered Call ETF

Roundhill Magnificent Seven Covered Call ETF

Roundhill Magnificent Seven Covered Call ETF ($MAGY) is trending as investors discuss its weekly dividend payouts and compare it to similar funds. Community members are evaluating its stability and potential for NAV erosion, particularly in comparison to other high-yield options. The ETF's consistent payouts and the possibility of generating daily income through a combination of different ETFs are also key discussion points.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community anticipates potential price movement, with some eyeing a "golden cross" and a test of the $100 mark. Discussions revolve around Litecoin potentially outperforming other cryptocurrencies like Zcash and whether an alt season is on the horizon. The recent launch of a Litecoin ETF and its potential impact are also being debated.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

LI is trending amidst discussions about its market position within the competitive Chinese EV sector and upcoming earnings, with community members weighing in on delivery numbers, new models like the i6, and potential impact from competitors like NIO. Some express concern over sales figures and market share, while others highlight the company's financial stability and expansion plans. Option activity and analyst ratings are also being closely monitored for potential catalysts.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

GLUE is trending as investors discuss the company's strong technical indicators and upcoming catalysts, including Phase 2b results and updates on the Novartis collaboration. Community members are pointing to the stock's potential for a significant squeeze due to high short interest and expressing excitement about its long-term prospects. The discussions also mention the broader context of molecular glue therapeutics and potential buyout scenarios.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy

Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.

Mustang Bio generated increased retail chatter on Monday after the company said that the FDA had awarded Orphan Drug Designation to its experimental CAR-T drug MB-101 for the treatment of astrocytomas and glioblastoma (GBM), two types of fast-growing brain tumors.The treatment, which targets the IL13Ra2 protein, is currently being studied in a Phase 1 trial.&nbsp;In early results published in Nature Medicine, MB-101 was well-tolerated, with 50% of patients seeing stable disease or better.&nbsp;Among them, two had partial responses, and two others achieved complete responses lasting 7.5 months and more than five and a half years.Mustang is also looking at a combo approach, pairing MB-101 with MB-108, an HSV-1-based oncolytic virus, in a regimen it calls MB-109.&nbsp;Preclinical studies suggest that MB-108 may help modify the tumor microenvironment, essentially turning "cold" tumors into "hot" ones to improve efficiency of MB-101 CAR-T cells.MB-108 already has Orphan Drug status for malignant glioma, and Mustang says the combination could allow MB-101 to move more effectively through the tumor, activate in the right spots, and target cancer cells more precisely.Both MB-101 and MB-108 are still enrolling patients in Phase 1 studies, including one at City of Hope, the other at The University of Alabama at Birmingham.&nbsp;However, moving the MB-109 program forward will depend on whether the company can secure more funding or land a partnership deal.Orphan Drug status gives MB-101 access to several FDA benefits, including seven years of market exclusivity if approved, tax breaks on clinical trial costs, and waived fees, which are all part of a program designed to support treatments for rare conditions affecting fewer than 200,000 people in the U.S.On Stocktwits, retail sentiment for Mustang Bio was ‘extremely bullish’ amid a 105,200% surge in 24-hour message volume.One user on Stocktwits suggested that shares of $MBIO could climb to the $15–$20 range if the company secures a partnership, noting the stock “has life” and is poised to grow, especially for those who bought in below $1.20.<stembedurl>https://stocktwits.com/Invest2live/message/620129007</stembedurl>Another user speculated that a partnership or buyout by a larger pharmaceutical company could be in play, calling the day’s FDA designation “great news” for&nbsp;<a href="https://stocktwits.com/symbol/MBIO">Mustang Bio</a>.<stembedurl>https://stocktwits.com/BostonBigBoyisBack/message/620124257</stembedurl>The stock has declined 68% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Mustang Bio Ignites Bullish Retail Buzz As FDA Grants Orphan Status To Brain Cancer Drug

The company is advancing a novel combination of its CAR-T drug MB-101 and oncolytic virus MB-108, with both treatments currently enrolling patients in Phase 1 trials. 

Equity

The biotech sector is already buzzing with retail investor interest as the new year begins. Here’s a look at the top three biotech stocks driving conversations on Stocktwits based on message volume jumps on the first trading day of 2025:Carmell Corp (CTCX): +58,100% Message VolumeRegenerative medicine biotech Carmell Corp surged into the spotlight after announcing an acquisition deal with PMGC Holdings’ Elevai Skincare subsidiary. The transaction includes $1.1 million in Carmell stock, $57,000 in cash, and contingent earnouts linked to Elevai’s product sales and revenue milestones.&nbsp;Carmell expects to acquire Elevai’s skincare and haircare portfolio, including a commercial team and inventory with $2.5 million in trailing revenue.&nbsp;Shares rocketed 148% on Thursday but saw some profit-taking early on Friday. Carmell’s stock lost roughly 80% last year.Mustang Bio (MBIO): +27,200% Message VolumeMustang Bio shares climbed 18% on Thursday and gained further in Friday’s pre-market, despite no apparent catalyst.&nbsp;In November, the company secured an extension from Nasdaq to meet compliance requirements and received FDA Orphan Drug Designation for MB-108, an oncolytic virus treatment for malignant glioma.&nbsp;While the stock fell nearly 85% in 2024, recent developments have sparked renewed optimism among investors.Revelation Biosciences (REVB): +9,150% Message VolumeRevelation Biosciences rose 42% on Thursday before sliding in Friday’s pre-market session without any catalyst.&nbsp;Retail buzz centers on its investigational therapy, Gemini, which received FDA clearance last month for a Phase 1b trial targeting chronic kidney disease patients.&nbsp;However, concerns around the company’s cash burn and financing moves have tempered investor enthusiasm. REVB shares dropped over 90% in 2024, leaving the stock a speculative favorite entering 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off

From acquisition news and FDA designations to fresh optimism for struggling stocks, these biotechs piqued Stocktwits users the most on the first trading day of 2025.

Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike PR Newswire VANCOUVER, BC, June 20, 2024 USA News...

Palantir, Mustang Bio, DraftKings, Micron, Tesla: Why These 5 Stocks Are On Investors' Radars Today

On Monday, major U.S. indices saw gains, with the Dow Jones Industrial Average closing nearly 0.5% higher at 38,778.10.
read more...

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application...

Mustang Bio stock climbs 9% amid drug development update

Mustang Bio stock climbs 9% amid drug development update...

Mustang Bio announces vision for CAR T-Cell therapy platform expansion

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the...

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Waltham, MA.

Mustang Bio Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.45
Prev Close	$1.46
Open	$1.44
Dividend Yield	0.00%
50-Day Moving Average	$1.55
Beta	1.19
Avg. Volume	115,826.81
PE Ratio	-0.47

52-Week High	$21.95
52-Week Low	$0.8926
Market Capitalization	$10.5M
EPS (Annual)	-$25.84
Price to Book	2.19
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MBIO
Mustang Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MBIO News

MBIOMustang Bio Inc